about
High-resolution structures of bacterially expressed soluble human CD59Using animal models to determine the significance of complement activation in Alzheimer's diseaseMolecular mechanisms of inflammation and tissue injury after major trauma--is complement the "bad guy"?A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritisThe Crystal Structure of Cobra Venom Factor, a Cofactor for C3- and C5-Convertase CVFBbDefining the CD59-C9 binding interactionMaggot excretions affect the human complement systemDisease-associated sequence variations congregate in a polyanion recognition patch on human factor H revealed in three-dimensional structureImplication of Complement System and its Regulators in Alzheimer’s DiseaseElucidation of the substrate specificity of the C1s protease of the classical complement pathway.Cooperative effects in the substrate specificity of the complement protease C1s.Chemical labelling of active serum thioester proteins for quantification.Interaction of two phagocytic host defense systems: Fcγ receptors and complement receptor 3.Critical role of effector macrophages in mediating CD4-dependent alloimmune injury of transplanted liver parenchymal cellsA new generation of potent complement inhibitors of the Compstatin family.Effect of complement C1q expression on hepatic ischemia-reperfusion injury in rats.The effects of eating marine- or vegetable-fed farmed trout on the human plasma proteome profiles of healthy men.Neuronal death in Alzheimer's disease and therapeutic opportunities.Endothelial cells elicit immune-enhancing responses to dengue virus infection.The immunobiology of Guillain-Barré syndromes.Complement and its breakdown products in SLE.Development of complement therapeutics for inhibition of immune-mediated red cell destructionTargeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE.The Structure-Activity Relationship between Marine Algae Polysaccharides and Anti-Complement Activity.Therapeutic inhibition of the alternative complement pathway attenuates chronic EAE.Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: A model agent for long-term complement inhibition in vivoFloridoside extracted from the red alga Mastocarpus stellatus is a potent activator of the classical complement pathway.The complement system in schizophrenia.Novel targets for immunotherapy in glomerulonephritis.Anticomplement therapy.The role of the complement system in CNS inflammatory diseases.Complement activation and inhibition in wound healing.Vasculitides and the Complement System: a Comprehensive Review.Does maggot therapy promote wound healing? The clinical and cellular evidence.Roles for endothelial cells in dengue virus infection.Structure and function of recombinant cobra venom factor.Investigating the structure of the factor B vWF-A domain/CD55 protein-protein complex using DEER spectroscopy: successes and pitfalls.Identification of the high affinity binding site in the Streptococcus intermedius toxin intermedilysin for its membrane receptor, the human complement regulator CD59.Absence of the complement regulatory molecule CD59a leads to exacerbated neuropathology after traumatic brain injury in mice.Soluble complement receptor 1 protects the peripheral nerve from early axon loss after injury.
P2860
Q24657819-EDA24744-8895-403A-BA8C-BD24D46126B6Q24796236-6236ACC1-8DB9-4C48-9631-8975DA218C3BQ26825724-DBFC3A9F-7E10-4154-8963-73C444BC18FDQ27645256-DA95454D-3423-4150-9748-D3F730E2CF2FQ27654785-9AD7A6A0-8063-42F6-B83F-64FA07F1AC2AQ28252317-1A7A9C7B-F679-4830-ADEB-FFC0157AD48DQ28278228-12D32FA1-CD17-463C-86A9-E861EA646FE6Q28301693-64DC2F4F-E116-4469-B780-B737F1F4414EQ28972502-B9C2F49C-6567-4062-8336-F2E3DB5A4EC0Q33223538-A9468442-A076-4948-BB90-1259AB7DA450Q33429247-D180F90E-F4AE-4933-9B51-EEA27CE9B7C3Q33996402-F5DD3915-EDFD-40B3-B9C6-D660D8976F54Q34452468-91DD6D16-D6C1-4EA3-86D1-F5D1FA5D9DB4Q34498297-04262D15-1BAD-42F1-8305-8EBB0672ADB8Q34984736-72B0FF1F-45D7-42A5-A111-598B2CC63785Q35190038-FE6B178E-2B6A-4874-8C1C-6D14F95EBB85Q35549463-4CD3FDB8-CC29-4D64-BAF6-DA5CCFC59188Q35889067-806F4642-DB94-486D-B33C-7021EE41C8ADQ36086727-278FE493-7D89-4743-9C2F-61F0688E5E4EQ36164122-41F9D7FC-BF7B-4856-9AE7-B2BF5AB31FDEQ36171508-EF98B673-BBEB-4F1E-997E-F99B8C0B6832Q36222203-EE0985D3-7018-4D3B-9862-695BE3DA87BCQ36401237-6A28B646-1AA5-4D68-84A1-778E93FA01B2Q36507103-70210DC6-7BEC-41A8-B318-0C830965382DQ36698228-40D0B3BC-386C-4376-B9AB-B2E692856707Q36947184-6DF963FE-3A66-413C-8FC1-E806E4443381Q36965221-FB75A029-F840-4EB6-8518-EFDB1AD25AB2Q37193661-C1E649AA-BA77-4425-8C57-11CE65B3ED0AQ37290692-6212D2BF-3935-4E4E-A244-B6B236A9A5FAQ37307880-219048D7-0C5E-47FF-886D-A3A55CF8F14FQ37754532-B18C1289-FF7F-40E0-9E65-A08A7BAB2B4FQ38076419-47466627-0793-4AF6-90D7-899DD79AB088Q38259908-8F30353B-9160-45B7-A695-330F926C2C5AQ38675562-B38B5EE6-20F3-4ED6-A629-608A966DF025Q40275323-B72AFDBD-4BF2-4E0B-BDEB-B7BB153F5FF0Q40558288-A38FEDD6-5DAF-4D6A-8DCE-E2FE89731E47Q40682669-87BBCC4C-B571-4853-BCE2-9C0756E1F14DQ41443185-052EE0C2-DE69-4B09-BC80-5EDCE952F1D1Q41771843-BC675BC5-606E-4DB3-B3D0-E54939936674Q43089398-44EDB757-4A3D-4015-ABBE-327E88D087CE
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Complement therapeutics; history and current progress.
@ast
Complement therapeutics; history and current progress.
@en
type
label
Complement therapeutics; history and current progress.
@ast
Complement therapeutics; history and current progress.
@en
prefLabel
Complement therapeutics; history and current progress.
@ast
Complement therapeutics; history and current progress.
@en
P1433
P1476
Complement therapeutics; history and current progress
@en
P2093
Claire L Harris
P304
P356
10.1016/S0161-5890(03)00111-1
P50
P577
2003-09-01T00:00:00Z